Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

188 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18)F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience.
Henriksen OM, Larsen VA, Muhic A, Hansen AE, Larsson HBW, Poulsen HS, Law I. Henriksen OM, et al. Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):103-112. doi: 10.1007/s00259-015-3183-6. Epub 2015 Sep 12. Eur J Nucl Med Mol Imaging. 2016. PMID: 26363903
A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Møller S, Grunnet K, Hansen S, Schultz H, Holmberg M, Sorensen M, Poulsen HS, Lassen U. Møller S, et al. Acta Oncol. 2012 Jul;51(6):797-804. doi: 10.3109/0284186X.2012.681063. Epub 2012 May 1. Acta Oncol. 2012. PMID: 22548369 Clinical Trial.
[MiRNA in glioblastomas--potentials and limitations].
Poulsen HS, von der Maase H. Poulsen HS, et al. Ugeskr Laeger. 2012 Mar 5;174(10):628. Ugeskr Laeger. 2012. PMID: 22395009 Danish. No abstract available.
Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Malmström A, Poulsen HS, Grønberg BH, Stragliotto G, Hansen S, Asklund T, Holmlund B, Łysiak M, Dowsett J, Kristensen BW, Söderkvist P, Rosell J, Henriksson R; Nordic Clinical Brain Tumor Study Group (NCBTSG). Malmström A, et al. Acta Oncol. 2017 Dec;56(12):1776-1785. doi: 10.1080/0284186X.2017.1332780. Epub 2017 Jul 4. Acta Oncol. 2017. PMID: 28675067 Clinical Trial.
Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.
Urup T, Dahlrot RH, Grunnet K, Christensen IJ, Michaelsen SR, Toft A, Larsen VA, Broholm H, Kosteljanetz M, Hansen S, Poulsen HS, Lassen U. Urup T, et al. Acta Oncol. 2016;55(4):418-22. doi: 10.3109/0284186X.2015.1114679. Epub 2016 Feb 1. Acta Oncol. 2016. PMID: 26828563
Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Hofland KF, Hansen S, Sorensen M, Engelholm S, Schultz HP, Muhic A, Grunnet K, Ask A, Costa JC, Kristiansen C, Thomsen C, Poulsen HS, Lassen U. Hofland KF, et al. Acta Oncol. 2014 Jul;53(7):939-44. doi: 10.3109/0284186X.2013.879607. Epub 2014 Jan 23. Acta Oncol. 2014. PMID: 24456504 Clinical Trial.
Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
Jakobsen JN, Hasselbalch B, Stockhausen MT, Lassen U, Poulsen HS. Jakobsen JN, et al. Expert Opin Pharmacother. 2011 Apr;12(5):825-33. doi: 10.1517/14656566.2011.566558. Epub 2011 Mar 9. Expert Opin Pharmacother. 2011. PMID: 21385110 Review.
[Gliomas in adults: primary non-surgical treatment].
Poulsen HS. Poulsen HS. Ugeskr Laeger. 2006 Nov 20;168(47):4082-5. Ugeskr Laeger. 2006. PMID: 17134603 Review. Danish.
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, Kosteljanetz M, Lassen U. Poulsen HS, et al. Acta Oncol. 2009;48(1):52-8. doi: 10.1080/02841860802537924. Acta Oncol. 2009. PMID: 19031176 Clinical Trial.
188 results
Jump to page